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Dendritic  cell  (DC)-based  vaccination  is  a  promising 
strategy  for  cancer  immunotherapy.  However,  clinical 
trials have indicated that immunosuppressive microen-
vironments  induced  by  tumors  profoundly  suppress 
antitumor immunity and inhibit vaccine efficacy, result-
ing in insufficient reduction of tumor burdens. To over-
come  these  obstacles  and  enhance  the  efficiency  of 
DC vaccination, we generated interleukin (IL)-12- and 
granulocyte-macrophage  colony-stimulating  factor 
(GM-CSF)-coexpressing  oncolytic  adenovirus  (Ad-∆B7/
IL12/GMCSF) as suitable therapeutic adjuvant to elimi-
nate immune suppression and promote DC function. By 
treating tumors with Ad-∆B7/IL12/GMCSF prior to DC 
vaccination, DCs elicited greater antitumor effects than 
in response to either treatment alone. DC migration to 
draining lymph nodes (DLNs) dramatically increased in 
mice treated with the combination therapy. This result 
was associated with upregulation of CC-chemokine ligand 
21 (CCL21+) lymphatics in tumors treated with Ad-∆B7/
IL12/GMCSF. Moreover, the proportion of CD4+CD25+ 
T-cells  and  vascular  endothelial  growth  factor  (VEGF) 
expression was decreased in mice treated with the com-
bination  therapy.  Furthermore,  combination  therapy 
using  immature  DCs  also  showed  effective  antitumor 
effects when combined with Ad-∆B7/IL12/GMCSF. The 
combination therapy had a remarkable therapeutic effi-
cacy on large tumors. Taken together, oncolytic adenovi-
rus coexpressing IL-12 and GM-CSF in combination with 
DC vaccination has synergistic antitumor effects and can 
act as a potent adjuvant for promoting and optimizing 
DC vaccination.
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5 April 2011. doi:10.1038/mt.2011.29
IntroductIon
Dendritic cells (DC) are potent antigen-presenting cells (APC) with 
a unique capability to induce primary immune responses to self or 
foreign antigens. DC-based vaccines are a promising strategy in 
cancer immunotherapy.1 DCs pulsed with tumor-associated anti-
gen can induce protective and therapeutic tumor-specific immune 
responses to various tumor types.2,3 Recently, DC-based vaccine 
clinical  trials  have  been  performed  with  patients  with  prostate 
cancer, melanoma, lymphoma, and renal carcinoma.4–7 However, 
beneficial patient responses were fewer than predicted. Although 
tumor-specific immune responses were seen in most of the patients, 
objective clinical responses were only observed in a few patients.
DCs have been reported to have significantly impaired biologi-
cal functions in advanced cancer patients, which might be associated 
with the failure of the DC vaccination in clinical trials.8,9 Emerging 
evidence indicates that this effect might be mediated by various fac-
tors produced by tumor cells. Tumor tissues can produce immuno-
suppressive molecules, such as vascular endothelial growth factor 
(VEGF),  transforming  growth  factor-β,  and  interleukin  (IL)-10. 
These molecules induce an immunosuppressive microenvironment 
within the tumors. The function of tumor-associated DCs may also 
be suppressed under these conditions.10 Therefore, DC vaccination 
efficacy may be improved by the addition of an adjuvant to reduce 
or eliminate tumor-induced immunosuppression.
Cytokine therapy has been reported to be an effective strat-
egy for cancer therapy.11 Ectopic cytokine expression in tumor 
tissues can induce strong antitumor immune responses, and can 
also convert the immunosuppressive tumor microenvironment to 
one with more antitumor characteristics. IL-12 is an important 
cytokine in innate and adaptive immunity that is able to enhance 
T-helper 1 cells (Th1) immunity, increase cytotoxic T-lymphocytes 
cytotoxicity,  and  inhibit  angiogenesis.12  Preclinical  and  clinical 
trials of IL-12-based immunotherapy have demonstrated strong 
antitumor immune responses.13–15 Previous studies reported that 
immunosuppressive conditions can be reversed by induction of 
intratumoral IL-12 expression. These results were associated with 
effector T-cell activation, Treg cell apoptosis induction, and cyto-
toxic  T-lymphocytes  infiltration.16  In  addition,  IL-12-induced 
IFN-γ-inducible protein 10 (IP-10) and Mig expression are strong 
inhibitors  of  tumor  angiogenesis.17  Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) is produced by a wide range 
of cell types and functions to stimulate proliferation, maturation, 
and function of APCs.18 Previous studies have demonstrated an 
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antitumor effect of GM-CSF in cancer immunotherapy, indicating 
that GM-CSF is a useful therapeutic agent in cancer therapy.19,20
Recently, adenovirus (Ad) vectors as efficient gene delivery 
systems have been widely used in cancer gene therapy. Cytokine 
gene therapy can induce sustained antitumor effect via sustained 
expression of therapeutic dose of cytokine in the local tumor tis-
sue and that can prolong the antitumor effect and reduce toxicity 
compared with treatment of recombinant cytokine protein.21–23 In 
an effort to overcome systemic cytokine toxicity, local injection 
of recombinant cytokine protein has been tried. But it was still 
not easily amenable in the clinics because it forced the continuous 
administration of cytokine.24 Moreover, Ad vectors can be modi-
fied to allow for replication in only cancer cells.25 Our previous 
studies have demonstrated that an oncolytic Ad can greatly amplify 
gene delivery efficacy in a cancer cell-restricted manner while they 
replicate.26,27 Furthermore, circulating Ad-specific neutralizing Ab 
may not significantly impact on the efficacy of local treatment of 
oncolytic Ad expressing cytokine, since there was no evident cor-
relation between the therapeutic efficacy and Ad-specific antibody 
(Ab) titer have been reported in clinical setting.28,29
In this report, we investigated the antitumor effects of an IL-12- 
and GM-CSF-coexpressing oncolytic Ad (Ad-∆B7/IL12/GMCSF) 
in  combination  with  DC  vaccination  in  a  murine  melanoma 
model. This combination therapy elicited strong and synergistic 
antitumor effects, correlated with the elimination of immunosup-
pression in tumor tissues, and facilitated DC migration to drain-
ing lymph nodes (DLNs). These preclinical results indicate that an 
oncolytic Ad coexpressing IL-12 and GM-CSF can act as a potent 
adjuvant for optimizing DC vaccination.
results
oncolytic Ad-mediated Il-12 and GM-csF expression
Ad-∆B7,  an  oncolytic  Ad,  was  mutated  in  the  retinoblastoma 
binding sites of E1A and had the E1B region deleted, as shown 
in Figure 1a. The cancer-specific viral replication and cytotoxic-
ity of Ad-∆B7 has been previously confirmed.25 To generate the 
Ad-∆B7/IL12/GMCSF oncolytic Ad, murine IL-12 and GM-CSF 
genes were inserted into the E1 and E3 regions of the Ad-∆B7 viral 
genome, respectively. Cultured murine melanoma B16-F10 cells 
were infected with Ad-∆B7/IL12/GMCSF at multiplicity of infec-
tion (MOIs) of 50, 100, and 500. As shown in Figure 1b,c a dose-
dependent increase in secreted IL-12 and GM-CSF was observed 
in cells infected with Ad-∆B7/IL12/GMCSF after 48 hour.
characterization of cultured dcs
To evaluate DC quality and phenotype, in vitro cultures of bone 
marrow-derived mature and immature DCs were assayed by flow 
cytometry. After the 8-day culture regimen, the cultures consisted 
of >80% DCs (Supplementary Figure S1a). After antigen-pulsing 
and  activation  by  lipopolysaccharide,  the  mature  DCs  showed 
markedly  increased  cell-surface  expression  of  the  costimula-
tory molecules CD40, CD80, CD86, and CC-chemokine recep-
tor 7 (CCR7), as compared with immature DCs (Supplementary 
Figure S1b,c).
therapeutic efficacy of Ad-∆B7/Il12/GMcsF 
combined with dcs in an established murine 
melanoma model
To evaluate the therapeutic efficacy of Ad-∆B7/IL12/GMCSF in 
combination  with  DCs  in  vivo, established B16-F10 melanoma 
tumors in C57BL/6 mice were intratumorally injected with three 
doses of Ad-∆B7/IL12/GMCSF on days 0–2, followed by three 
injections of DCs on days 3–5. Treatment groups included phos-
phate-buffered saline (PBS)-only control, Ad-∆B7/IL12/GMCSF 
only (5 × 109 viral particle (VP)/injection), DCs only (1 × 106/injec-
tion), or a combination of DCs and Ad-∆B7/IL12/GMCSF, referred 
to as the combination therapy. In parallel, one group of mice was 
given a treatment regimen of a high dose of Ad-∆B7/IL12/GMCSF 
I
T
R
I
T
R
E1A
E1A IL-12
∆E1B
Ad-∆B7
Ad-∆B7/IL12/GMCSF
∆E3
ψ
ψ
IX
IX
Ad genome
Ad genome GM-CSF
E4
E4
I
T
R
I
T
R
a
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
50 MOI 100 MOI 500 MOI
I
L
-
1
2
 
(
p
g
/
m
l
)
b 700,000
600,000
500,000
400,000
300,000
200,000
100,000
0
50 MOI 100 MOI 500 MOI
G
M
-
C
S
F
 
(
p
g
/
m
l
)
c
Figure 1  characterization of oncolytic adenovirus coexpressing interleukin (Il)-12 and granulocyte-macrophage colony-stimulating factor 
(GM-csF). (a) Schematic representation of the genomic structures of adenovirus (Ad) Ad-∆B7 and Ad-∆B7/IL12/GMCSF. Ad-∆B7 contains mutated 
E1A (open star, mutation at Rb protein–binding site), but lacks E1B 19 and 55 kDa (∆E1B), and E3 region (∆E3); the murine IL-12 and murine GM-CSF 
were inserted into E1 and E3 region of Ad genome, respectively. The level of IL-12 (b) and GM-CSF (c) expression was confirmed in B16-F10 cells 
after infection with Ad-∆B7/IL12/GMCSF at different MOIs. Cell culture supernatants were collected at 48 hour after infection, and the level of IL-12 
and GM-CSF was quantified by conventional enzyme-linked immunosorbent assay kit. Data represent the mean ± SE of triplicate experiments, and 
similar results were obtained from at least three separate experiments. MOI, multiplicity of infection.1560  www.moleculartherapy.org  vol. 19 no. 8 aug. 2011     
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(5 × 1010 VP/injection) in combination with DCs (1 × 106/injec-
tion), referred to as the high-dose combination therapy.
Control mice treated with PBS alone showed aggressive tumor 
growth and rapidly formed large tumors (over 2,500 mm3) by day 8 
(Figure 2a). In contrast, mice treated with Ad-∆B7/IL12/GMCSF 
or DCs alone showed significant inhibition of tumor growth. On 
day 8, the mean tumor volumes in mice treated with DCs alone, 
Ad-∆B7/IL12/GMCSF  alone,  the  combination  therapy,  or  the 
high-dose combination therapy were 1,031 ± 443, 410 ± 170, 210 ± 
24, and 177 ± 19 mm3, respectively. These data correlate to 63, 85, 
92, and 93% tumor growth inhibition, respectively, as compared to 
PBS alone controls. Tumor growth inhibition was statistically sig-
nificant in mice treated with the combination therapy as compared 
with individual treatment groups (P < 0.05 versus DCs or Ad-∆B7/
IL12/GMCSF).  The  high-dose  combination  therapy  showed  an 
even greater antitumor effect than combination therapy (on day 
26, P < 0.05 versus combination therapy). In addition, the median 
survival of mice treated with Ad-∆B7/IL12/GMCSF alone, DCs 
alone, the combination therapy, or high-dose combination therapy 
was 18, 18, 28, and over 90 days, respectively. All treatment groups 
showed significantly prolonged survival as compared to control 
mice (P < 0.01, Figure 2b). Importantly, four out of six mice treated 
with the high-dose combination therapy achieved complete remis-
sion and survived over 90 days. These results suggest that Ad-∆B7/
IL12/GMCSF in combination with DCs can induce a potent anti-
tumor effect in the B16-F10 melanoma model.
Il-12 and GM-csF expression and immune  
cell infiltration in treated tumor tissues
To examine the mechanisms of the observed antitumor effects, 
IL-12 and GM-CSF expression and immune cell infiltration in the 
tumor tissues were examined. Expression of IL-12 and GM-CSF 
was very minimal in tumors treated with PBS, but was present in 
tumors treated with Ad-∆B7/IL12/GMCSF or DCs (Figure 3a,b). 
Tumors treated with the combination therapy showed markedly 
enhanced IL-12 and GM-CSF expression relative to tumors treated 
with Ad-∆B7/IL12/GMCSF or DCs alone. This finding was even 
more dramatic in tumors treated with the high-dose combination 
therapy.
Histological  analyses  revealed  enhanced  tumor  necrosis  in 
tumor tissues from mice treated with the combination therapy 
as compared with individual treatments. Significantly, nearly all 
tumor cells were eliminated from mice treated with the high-
dose combination therapy. Immunohistochemical analyses using 
CD4-, CD8-, CD11c-, and CD86-specific Abs were performed 
to identify the immune cells that infiltrated the tumor tissues. 
Significantly greater numbers of CD4+ T-cells, CD8+ T-cells, and 
CD11c+ DCs were observed in tumors treated with the combi-
nation therapy than in tumors receiving individual treatments 
(Figure 3c). Correlating with the data in Figure 2, tumors treated 
with the high-dose combination therapy showed increased levels 
of tumor-infiltrating T-cells and DCs. In addition, the expression 
of CD86 as a marker of activated APCs was significantly increased 
in tumors treated with the combination therapies as compared to 
the individual treatments.
VeGF expression and tumor angiogenesis  
is inhibited by combination therapy
IL-12  and  E1A  protein  have  been  reported  to  inhibit  tumor 
angiogenesis and downregulate VEGF expression.30,31 As shown 
in Figure 4a, VEGF expression was decreased in tumors from all 
treatment groups as compared to the PBS control, with a more 
robust reduction in the combination therapy group (P < 0.05 ver-
sus DCs alone). As expected, VEGF expression was decreased to 
the lowest levels in tumors treated with the high-dose combina-
tion therapy (P < 0.05 versus the combination therapy).
Tumor angiogenesis was examined by immunohistochemical 
analysis using a CD31-specific Ab. A reduced number of CD31+ 
vessels were observed in mice treated with any of the individual 
or  combination  treatments  as  compared  to  the  PBS  controls 
(Figure 4b,c). Consistent with the data above, the decrease in 
CD31+ vessels was statistically greater in the combination-treated 
tumors  than  in  tumors  that  received  DCs  or  Ad-∆B7/IL12/
GMCSF alone (P < 0.05). Likewise, the high-dose combination 
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Figure 2  Antitumor effect of Ad-∆B7/Il12/GMcsF in combination with dendritic cell (dcs). (a) Pre-established B16-F10 tumor was injected 
with phosphate-buffered saline (PBS) (open diamonds), DCs (open squares), Ad-∆B7/IL12/GMCSF (filled triangles), Ad-∆B7/IL12/GMCSF plus DCs 
(filled squares), or Ad-∆B7/IL12/GMCSF (H; high-dose of Ad) plus DCs (filled diamonds). Tumor growth was monitored every day. (b) Survival 
percentage of tumor-bearing mice following treatment with Ad-∆B7/IL12/GMCSF and/or DCs. Tumor size over 3,000 mm3 was regarded as death. 
Data points represent the mean ± SE. All results in this figure represent results of at least seven mice per group. *P < 0.05. GM-CSF, granulocyte-
macrophage colony-stimulating factor; IL, interleukin.Molecular Therapy  vol. 19 no. 8 aug. 2011  1561
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therapy showed the greatest decrease (P < 0.05 versus the combi-
nation therapy) to nearly complete inhibition of angiogenesis.
combination therapy promotes dc migration  
to draining lymphnodes
To explore whether DC migration to DLNs is promoted by com-
bination  therapy,  DCs  were  labeled  with  a  fluorescent  probe, 
CMTPX (Supplementary Figure S2a). A significantly increased 
percentage of CMTPX+ DCs was observed in DLNs from mice 
treated with the combination therapy than from mice treated 
with DCs alone (P < 0.01). This finding was enhanced in mice 
treated with the high-dose combination therapy (P < 0.05 ver-
sus the combination therapy; Figure 5a, Supplementary Figure 
S2b).  Moreover,  combination  therapy  significantly  augmented 
the proportion of CD11c+ DCs in DLNs, implying that com-
bination therapy also promotes migration of endogenous DCs 
to  DLNs  (P  <  0.05  versus  Ad-∆B7/IL12/GMCSF  plus  DCs; 
Figure 5b and Supplementary Figure S2c). Mice treated with 
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Figure 3  Generation of antitumor immune response by Ad-∆B7/Il12/GMcsF in combination with dendritic cell (dcs). The level of interleukin 
(IL)-12 (a) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (b) expression in tumor tissues treated with phosphate-buffered saline 
(PBS), DCs, Ad-∆B7/IL12/GMCSF, Ad-∆B7/IL12/GMCSF plus DCs, or Ad-∆B7/IL12/GMCSF (H; high-dose of Ad) plus DCs. (c) Histological and immu-
nohistochemical analysis in tumor tissues treated with Ad-∆B7/IL12/GMCSF and/or DCs. Tumor tissues were collected from mice at 3 days after final 
treatment, and paraffin section of tumor tissue was stained with hematoxylin and eosin (H&E) (top two rows, original magnification: ×40 and ×400). 
Immune cells infiltrated in tumor tissues were examined by anti-CD4 antibody (third row), anti-CD8 antibody (fourth row), anti-CD11c antibody 
(fifth row) and anti-CD86 antibody (bottom row). Original magnification: ×400. Data points represent the mean ± SE of at least three mice per group, 
and similar results were obtained from at least three separate experiments. *P < 0.05; **P < 0.01.1562  www.moleculartherapy.org  vol. 19 no. 8 aug. 2011     
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the combination therapy showed significantly increased total cell 
numbers in DLNs as compared to mice treated with DCs alone 
(P < 0.01; Figure 5c). Consistent with augmented total cell num-
bers in DLN from mice treated with the combination therapies, 
the expression of proliferating cell nuclear antigen as a marker 
for cellular proliferation was significantly increased compared to 
the individual treatments (Figure 5d). These results suggest that 
the combination therapy significantly promotes DC migration to 
DLNs and induces proliferation of immune cells in the DLNs.
upregulation of ccl21+ lymphatic vessels in tumor 
tissues treated with the combination therapy
A previous study reported that DC migration to DLNs depends on 
CCR7/CC-chemokine ligand 21 (CCL21) interaction and tumor 
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Figure 4  decreased vascular endothelial growth factor (VeGF) expression and angiogenesis in tumors treated with combination therapy. 
Tumors were treated with phosphate-buffered saline (PBS), dendritic cells (DCs), Ad-∆B7/IL12/GMCSF, Ad-∆B7/IL12/GMCSF plus DCs, or Ad-∆B7/
IL12/GMCSF (H; high-dose of Ad) plus DCs, and harvested from mice at 3 days after final treatment. (a) The level of VEGF expression in tumor tissues 
was quantified by conventional enzyme-linked immunosorbent assay. *P < 0.05. (b) CD31+ microvessel immunohistochemistry in the tumor tissues 
treated with PBS, DC, Ad-∆B7/IL12/GMCSF, Ad-∆B7/IL12/GMCSF plus DCs, or Ad-∆B7/IL12/GMCSF (H) plus DCs. Original magnification: ×100 and 
×400. (c) The means of CD31+ vessel density in microscopic field for each treatment group (×200). Data points represent the mean ± SE of three 
mice per group, and similar results were obtained from at least two separate experiments. *P < 0.05; **P < 0.01. GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IL, interleukin.
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Figure 5  dendritic cells (dc) migration to the draining lymph nodes (dlns). Ex vivo generated DCs were labeled with CMTPX. Two days after 
final treatment, single cells were collected from DLNs and the migration was quantified by fluorescence-activated cell sorting analysis. (a) The num-
ber of CMTPX+ DCs in DLNs from mice treated with phosphate-buffered saline (PBS), DC, Ad-∆B7/IL12/GMCSF plus DCs, or Ad-∆B7/IL12/GMCSF 
(H; high-dose of Ad) plus DCs were quantified on a fluorescence-activated cell sorter, and data from 50,000 events were represented. (b) CD11c+ 
DCs in the DLNs from mice treated with Ad-∆B7/IL12/GMCSF and/or DCs. (c) Total cell number of DLNs from different groups of mice. Data points 
represent the mean ± SE of triplicate experiments. All results in this figure represent results of at least three mice per group, and similar results were 
obtained from at least two separate experiments. *P < 0.05; **P < 0.01. (d) Immunohistochemical staining of proliferating cell nuclear antigen in 
draining lymph node tissues. Original magnification: ×400. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin.Molecular Therapy  vol. 19 no. 8 aug. 2011  1563
© The American Society of Gene & Cell Therapy
DC Vaccination and IL-12/GM-CSF Gene Therapy
necrosis factor (TNF)-α regulation of CCL21+ lymphatics within 
the tissue.32 Tumors from mice treated with Ad-∆B7/IL12/GMCSF 
alone showed a significantly increased number of CCL21+ lym-
phatic vessels around the tumor tissues (P < 0.01 versus PBS and 
DCs alone; Figure 6a,b). Combination therapy greatly enhanced 
the number of CCL21+ lymphatic vessels as compared with the 
virus  alone-treatment  group  (P  <  0.05).  Moreover,  the  high-
dose combination therapy showed the greatest level of CCL21+ 
lymphatics in the tumor tissues (P < 0.01 versus the combination 
therapy).
To better understand the mechanism of CCL21+ lymphatic 
vessel  upregulation  in  tumors  treated  with  the  combination 
therapy, expression of TNF-α in the tumors was measured by 
enzyme-linked  immunosorbent  assay  (ELISA).  TNF-α  lev-
els were augmented in the tumors treated with Ad-∆B7/IL12/
GMCSF or DCs alone and were significantly increased in the 
combination therapy group (P < 0.05 versus individual treat-
ments;  Figure  6c).  Consistently,  the  high-dose  combination 
therapy  group  had  the  highest  levels  of  TNF-α  expression 
(P < 0.05 versus combination therapy). These results indicate 
that increased TNF-α expression in tumor tissues treated with 
combination therapies might be the cause of the upregulation of 
CCL21+ lymphatics.
the cd4+cd25+ t-cell population decreased in dlns 
of mice treated with the combination therapy
CD4+CD25+ T-cells are important immune suppressors whose 
development is partially regulated by VEGF. As described above, 
the  expression  of  VEGF  was  markedly  decreased  in  tumors 
treated with the combination therapy (Figure 4a). To evalu-
ate changes in the CD4+CD25+ T-cell population within the 
DLNs, lymphocytes were collected from DLNs of mice treated 
with  PBS,  DCs,  Ad-∆B7/IL12/GMCSF,  or  the  combination 
therapy. The CD4+CD25+ T-cell population from the DLNs 
was significantly decreased in mice treated with Ad-∆B7/IL12/
GMCSF as compared to mice treated with PBS or DCs (P < 0.01; 
Figure 7 and Supplementary Figure S3). The decrease in the 
CD4+CD25+ T-cell population was still greater in mice treated 
with the combination therapy (P < 0.05 versus Ad-∆B7/IL12/
GMCSF alone).
Antitumor effect induced by Ad-∆B7/Il12/GMcsF  
in combination with immature dcs
Immature DCs differentiated from progenitor cells can actively 
uptake  and  process  exogenous  antigen.  Following  maturation, 
DCs downregulate their antigen acquisition and processing abili-
ties and display increased immunogenicity. Immature DCs dif-
fer from mature DCs pulsed with tumor antigen in vitro in that 
immature DCs can take up in situ tumor antigens. B16-F10 mela-
noma models were used to evaluate the therapeutic effects of com-
bination therapy using immature DCs in comparison to mature 
DCs.  Similar  antitumor  effects  were  observed  in  combination 
therapies using mature or immature DCs (Figure 8a). This find-
ing indicates that the combinatorial strategy using the cytokine-
expressing oncolytic Ad can promote maturation of immature 
DCs within the tumor tissue. Therefore, Ad-∆B7/IL12/GMCSF-
mediated expression of IL-12 and GM-CSF prior to DC injection 
might reverse the immunosuppressive microenvironment within 
the tumor, resulting in a microenvironment favorable to the matu-
ration and function of immature DCs.
We further assessed the effect of the treatment schedule of 
oncolytic Ad and DCs on gross antitumor efficacy. The antitumor 
efficacy and survival rates were significantly improved in tumors 
treated  with  Ad-∆B7/IL12/GMCSF  prior  to  DC  vaccination 
(Figure 8b,c; filled triangles) or in tumors treated with Ad-∆B7/
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Figure 6  Visualization and quantification of ccl21+ lymphatic ves-
sels in tumors treated with Ad-∆B7/Il12/GMcsF and/or dendritic 
cells  (dcs).  Tumors  harvested  from  mice  treated  with  phosphate-
buffered saline (PBS), DC, Ad-∆B7/IL12/GMCSF, Ad-∆B7/IL12/GMCSF 
plus DCs, or Ad-∆B7/IL12/GMCSF (H; high-dose of Ad) plus DCs were 
embedded in paraffin and sectioned. (a) Immunohistochemical staining 
of CCL21+ lymphatic vessels in tumor tissues. Original magnification: 
×100 & ×400. (b) The means of CCL21+ lymphatic vessel in microscopic 
field (×200). (c) Tumor necrosis factor (TNF)-α expression in the tumor 
tissues was measured by conventional enzyme-linked immunosorbent 
assay. Data points represent the mean ± SE of triplicate experiments. All 
results in this figure represent results of at least three mice per group, 
and  similar  results  were  obtained  from  at  least  two  separate  experi-
ments. *P < 0.05; **P < 0.01. GM-CSF, granulocyte-macrophage colony-
stimulating factor; IL, interleukin.
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Figure 7  cd4+cd25+ t-cells in draining lymph nodes (dlns) from 
mice treated with Ad-∆B7/Il12/GMcsF and/or dendritic cells (dcs). 
DLNs were collected from mice treated with phosphate-buffered saline 
(PBS),  DC,  Ad-∆B7/IL12/GMCSF,  Ad-∆B7/IL12/GMCSF  plus  DCs,  or 
Ad-∆B7/IL12/GMCSF  (H;  high-dose  of  Ad)  plus  DCs.  Proportion  of 
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measured  by  fluorescence-activated  cell  sorting  analysis.  Data  points 
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were  obtained  from  at  least  two  separate  experiments.  *P  <  0.05; 
**P < 0.01. GM-CSF, granulocyte-macrophage colony-stimulating fac-
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IL12/GMCSF and DCs on alternating days (open diamonds) as 
compared to tumors treated with Ad-∆B7/IL12/GMCSF follow-
ing  DC  vaccination  (filled  squares)  (P  < 0.05).  Clearly,  tumor 
treatment with Ad-∆B7/IL12/GMCSF prior to DC vaccination 
has a higher antitumor efficacy.
The antitumor effect of combination therapies on large tumors 
which  represents  late-stage  tumors  was  assessed.  Mice  were 
treated with high-dose combination therapy when tumor volumes 
reached three different sizes: 117.54 ± 14.29, 288.89 ± 39.96, and 
573.66 ± 110.15 mm3. Potent antitumor effects were induced by 
high-dose combination therapy even when the initial tumor size 
reached over 500 mm3. However, the therapeutic efficacy was sig-
nificantly improved when the initial tumor sizes were <300 mm3. 
These data suggest that combination therapy can elicit potent anti-
tumor effects even when the tumor burden is large and in late-
stage tumors.
dIscussIon
Tumor-induced  immune  suppression  mediated  by  a  variety 
of  molecules,  such  as  VEGF,  IL-10,  and  transforming  growth 
factor-β,  is  a  major  problem  faced  by  cancer  immunotherapy. 
These molecules produced by several tumor compartments not 
only impair the recruitment and maturation of DCs and T-cells 
in the tumor tissue, but also induce abnormal systemic DC dif-
ferentiation and activation. This immune modulation is a major 
obstacle  in  DC-based  cancer  vaccination.33,34  Therefore,  many 
recent studies have focused on optimizing DC vaccination proto-
cols to overcome tumor-induced immune suppression.
IL-12  is  a  potent  immune-stimulatory  cytokine  that  can 
reverse  tumor  microenvironment  immunosuppression.16  DCs 
activated in the presence of IL-12, IL-18, and anti-CD40 antibody 
have been shown to potently improve antitumor immunity.35 In 
addition, DCs transduced with the IL-12 gene and melanoma-
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Figure 8  therapeutic efficacy of combination therapy based on the dendritic cells (dc) maturation, treatment schedule, and tumor size. 
(a) Tumor-bearing mice were treated with Ad-∆B7/IL12/GMCSF in combination with mature or immature DCs. Similar antitumor effects were 
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associated antigen (gp100) were shown to induce more effective 
tumor-specific immune responses by upregulating costimulatory 
molecules and by improving T-cell stimulation.36 Therefore, IL-12 
is  a  good  candidate  for  combination  with  DC  vaccinations  to 
improve the therapeutic efficiency. GM-CSF is associated with the 
function of APCs, but GM-CSF also plays an important role in the 
development of DCs in vitro and in vivo.37 Recently, the therapeu-
tic efficacy of DC vaccination for the treatment of murine renal 
cell carcinomas was improved when combined with GM-CSF-
secreting tumor cells.38 To improve the efficacy of DC vaccination, 
IL-12 and GM-CSF were selected for use in combination therapies 
to activate and enhance host immune responses.
This study demonstrates that the combination of DC vacci-
nation and oncolytic Ad coexpressing both IL-12 and GM-CSF 
greatly  enhanced  the  antitumor  effects  and  survival  rates  in  a 
murine  melanoma  model,  as  compared  with  individual  treat-
ments (Figure 2a,b). Moreover, IL-12 levels were also markedly 
enhanced in tumor tissues that received the combination therapy 
(Figure 3a). IL-12 not only enhances Th1 immunity and cytotoxic 
T-lymphocytes  cytotoxicity,  but  at  high  concentrations,  IL-12 
can also activate natural killer cells. Activated natural killer cells 
promote DC maturation, which induces a positive feedback loop 
in that the mature DCs secrete additional IL-12.39 In addition, 
GM-CSF  secreted  from  Ad-∆B7/IL12/GMCSF-infected  tumor 
cells can also recruit and induce maturation of DCs within tumor 
tissues (Figure 3c). Taken together, these findings suggest that 
IL-12 and GM-CSF are potent stimuli that can activate and boost 
the host immune system, and can also synergistically promote DC 
vaccination efficacy.
VEGF not only plays a critical role in the development of tumor 
angiogenesis, but also inhibits the differentiation and maturation 
of DCs.40 In  vivo administration of neutralizing VEGF-specific 
antibody can improve the function of DCs and increase the num-
ber of mature DCs in tumor-bearing mice.41 IL-12 downregulated 
VEGF expression in a murine breast cancer model,42 and inhib-
ited tumor angiogenesis.31 Here, VEGF expression was inversely 
related to IL-12 expression. Specifically, VEGF expression was sig-
nificantly reduced in tumors treated with the combination therapy 
as compared with control tumors or tumors that received individ-
ual treatments (Figure 4a). Likewise, enhanced antiangiogenesis 
was observed in tumors that received the combination treatments 
(Figure 4b,c). These data suggest that IL-12-mediated antiangio-
genesis played a role in the combination therapy-induced anti-
tumor effect. Importantly, reduction of VEGF expression due to 
the combination therapy might contribute to the reduction of the 
tumor microenvironment immunosuppression, therefore enhanc-
ing DC vaccination efficacy.
Following  maturation,  DCs  upregulate  costimulatory  mol-
ecules and acquire the ability to migrate to regional lymph nodes. 
Migration of DCs to regional lymph nodes is an essential step in 
the induction of immune responses and, therefore, is an important 
aspect of DC vaccination.33 However, only a small proportion of 
injected DCs migrated to DLNs in cancer patients during clinical 
trials of DC vaccination.43,44 To increase the efficiency of DC vac-
cination, DC migration to DLNs must be enhanced. In this study, 
mice treated with the combination therapy showed significantly 
increased numbers of endogenous as well as exogenously injected 
DCs that migrated to the DLNs (Figure 5a,b). This migration 
likely played a significant role in enhancing DC vaccination effi-
cacy in tumor-bearing mice. This finding is in line with our pre-
vious study that indicated that DC migration can be promoted 
when DCs are combined with oncolytic Ad coexpressing IL-12 
and 4-1BB ligand.45
Migration of mature DCs to draining lymph nodes is driven 
by the interaction of high levels of CCR7 on mature DCs with 
its ligand, CCL21 in the lymphatics.46 Mice treated with Ad-∆B7/
IL12/GMCSF alone or in combination with DCs showed a mark-
edly increased number of CCL21-positive lymphatic vessels sur-
rounding tumor tissues as compared with mice treated with PBS 
or DCs alone (Figure 6a,b). This suggests that the increased DC 
migration in the combination therapy group was due to upregu-
lation of CCL21+ lymphatic vessels in the tumor tissue. Martin-
Fontecha et al. reported that TNF-α-induced tissue inflammation 
greatly  increases  DC  migration  to  DLNs  due  to  upregulation 
of  CCL21  expression  on  lymphatic  vessels  in  situ.32  Therefore, 
TNF-α may be an inflammatory stimuli associated with the regu-
lation of CCL21 expression on the endothelial cells of lymphatics. 
Interestingly, combination therapy significantly increased the level 
of TNF-α in tumors (Figure 6c). TNF-α was likely secreted by 
tumor-infiltrating T-cells, monocytes, and macrophages recruited 
to the CCL21+ lymphatic vessels in the tumor tissues by IL-12 
and  GM-CSF  expressed  by  Ad-∆B7/IL12/GMCSF.  However,  it 
remains  unclear  whether  IL-12  or  GM-CSF  directly  regulates 
CCL21 expression on endothelial cells of the lymphatics.
Emerging evidence suggests that CD4+CD25+ T cell-mediated 
immune suppression is a crucial tumor immune evasion mechanism 
and is often a barrier for successful tumor immunotherapy. A previ-
ous study demonstrated that local IL-12 expression by tumor tissues 
can reverse the tumor immune suppression by inducing apoptosis 
of CD4+CD25+Foxp3+ T-cells.16 In our study, the CD4+CD25+ 
T-cell population was reduced in the DLNs of tumor-bearing mice 
treated with Ad-∆B7/IL12/GMCSF alone or in combination with 
DCs as compared with the PBS and DCs-alone treatment groups. 
It is likely that the high level of IL-12 expressed in the tumor tissue 
contributed to CD4+CD25+ T-cell elimination (Figure 7). In addi-
tion, VEGF is associated with the development of CD4+CD25+ 
T-cells in tumor-bearing mice and cancer patients.47,48 Therefore, the 
decreased VEGF expression in the tumors from mice that received 
the combination therapy likely contributed to the CD4+CD25+ 
T-cell population reduction in the DLNs.
Interestingly, combination therapy using immature DCs had 
similar antitumor effects as the combination therapy using mature 
DCs (Figure 8a). IL-12 and GM-CSF secreted from Ad-∆B7/IL12/
GMCSF likely directly activated the immature DCs or induced an 
immune response that produced a number of immune-stimulating 
factors to circumvent the immunosuppressive microenvironment. 
Moreover, injected immature DCs can efficiently uptake tumor 
antigens in situ that were generated by oncolytic Ad-mediated 
oncolysis of cancer cells.
The order of virus and DC injection also affected the anti-
tumor effects of the combination therapies (Figure 8b,c). These 
results indicate that injection of the cytokine-expressing oncolytic 
Ad prior to DC vaccination can reduce immune suppression and 
induce favorable immune response conditions within the tumor 1566  www.moleculartherapy.org  vol. 19 no. 8 aug. 2011     
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tissue, resulting in improved efficacy of DC vaccination. In addi-
tion, combination therapy also elicited notable antitumor effects in 
large tumors (Figure 8d,e), suggesting that combination therapy 
can overcome the limitation of DC vaccinations to reduce tumor 
burden in established solid tumors.49
This study demonstrates synergistic antitumor effects between 
Ad-∆B7/IL12/GMCSF and DCs in a murine melanoma model. 
The mechanism is associated with the elimination of immune 
suppression in the tumor and promotion of DC maturation and 
migration to DLNs. These findings provide the basis for a feasible 
oncolytic Ad-based cytokine gene therapy in combination with 
DC vaccination for cancer treatment in the clinic.
MAterIAls And Methods
Cell lines and cell culture. B16-F10 (murine melanoma) cells were main-
tained in Dulbecco’s modified Eagle’s medium (Gibco BRL, Grand Island, 
NY) supplemented with 10% fetal bovine serum (Gibco BRL), 100 IU/ml 
penicillin, and 100 μg/ml streptomycin.
Mice. C57BL/6 mice were obtained from SLC (Tokyo, Japan). Mice were 
used at 6–7 week of age, and all animal studies were performed accord-
ing to institutionally approved protocols at Yonsei University College of 
Medicine.
Adenoviral vectors. To generate an Ad expressing IL-12 and GM-CSF 
at the E1 and E3 region, respectively, we first constructed an E3 shuttle 
vector expressing GM-CSF. The murine GM-CSF gene was excised from 
pCDNA3.1/GMCSF using NheI and XhoI, and sub-cloned into the Ad E3 
shuttle vector, pSP72-E3, generating a pSP72/E3/GMCSF E3 shuttle vector. 
The newly constructed pSP72/E3/GMCSF was then cotransformed with 
an Ad total vector (pvmdl324BstBI) into Escherichia coli BJ5183, yielding 
a pdl324∆E3/GMCSF Ad plasmid. Structure of the resultant recombinant 
vector was confirmed by restriction enzyme digestion and PCR analysis. 
To construct an Ad E1 shuttle vector expressing IL-12, murine IL-12 gene 
excised  from  pCA14/IL1249  was  sub-cloned  into  pXC1∆B7  E1  shuttle 
vector,25 generating a pXC1∆B7/IL12 E1 shuttle vector. The newly con-
structed pXC1∆B7/IL12 E1 shuttle vector was then cotransformed with 
pdl324∆E3/GMCSF into E. coli BJ5183 for homologous recombination, 
generating a pAd-∆B7/IL12/GMCSF Ad vector (Figure 1a). All viruses 
were propagated in 293 cells and purified by CsCl density purification, 
dissolved in storage buffer (10 mmol/l Tris, 4% sucrose, 2 mmol/l MgCl2), 
and stored at −80 °C. Viral particle numbers were calculated from mea-
surements of absorbance at 260 nm (A260), where one absorbency unit is 
equivalent to 1012 viral particles/ml. The infectious titers (plaque-forming 
units per milliliter) were determined by limiting dilution assay on 293 
cells. The particle/plaque-forming unit ratio for Ad-∆B7 and Ad-∆B7/
IL12/GMCSF were 23.7:1 and 20.9:1, respectively. The MOI was calcu-
lated from infectious titers.
Generation of bone marrow-derived DC. Bone marrow cells were har-
vested from flushed marrow cavities of femurs and tibias of C57BL6 
mice  under  aseptic  conditions.  The  cells  were  depleted  of  erythro-
cytes using RBC lysis buffer (Sigma, St Louis, MO) and were cultured 
in complete RPMI 1640 media (Gibco BRL) supplemented with 10% 
fetal  bovine  serum,  GM-CSF  (10 ng/ml,  ENDOGEN,  Woburn,  MA), 
and IL-4 (10 ng/ml, ENDOGEN), 2-mercaptoethanol 50 μmol, 100 IU/
ml penicillin, and 100 μg/ml streptomycin. On day 2, the nonadherent 
cells were removed and the plates were replenished with fresh complete 
media containing GM-CSF and IL-4. On day 4, culture supernatant was 
collected and centrifuged, and the cell pellet was resuspended in fresh 
media containing cytokines and returned to the plate. On day 6, the DCs 
were incubated with the tumor lysate (50 μg/ml) for 24 hour lipopolysac-
charide (1 μg/ml, Sigma) were added at day 7 for DCs maturation. After 
incubation for 24 hours, mature DCs were harvested and used in follow-
ing studies. Immature DCs were cultured at same condition for 6 days as 
described above. But, the cell was not exposed to the tumor lysate and 
lipopolysaccharide.
Fluorescence-activated cell sorting (FACS) analysis. For the phenotypic 
analysis, the DCs were stained with surface molecules using immunoflu-
orescence and analyzed by FACS analysis. Cells were stained with anti-
mouse CD11c, CCR7, CD40, CD80, CD86, or MHC I/II (Pharmingen, 
San Diego, CA) Ab at 4 °C for 45 minutes. After twice of PBS washing, 
the cells were incubated with fluorescein isothiocyanate-conjugated goat 
anti-rat IgG secondary Ab at 4 °C for 15 minutes. For the assessment of 
CD4+CD25+ T-cell population in the DLN, single cells were obtained 
from DLN after mechanical dissociation. The cells were stained with anti-
mouse CD4 (phycoerythrin) and anti-mouse CD25 (fluorescein isothio-
cyanate) Ab at 4 °C for 45 minutes. All samples were analyzed on a BD 
Biosciences BD-LSR II Analytic Flow Cytometer, using FACSDiva soft-
ware (BD Biosciences, San Jose, CA).
In vivo antitumor effect. B16-F10 cells (5 × 105) were injected subcutane-
ously into the right abdomen of 6–7 week-old male C57BL/6 mice. When 
the tumor volumes reached of around 120–130 mm3, mice were sorted into 
groups with similar means of tumor volumes. Treatment groups included 
PBS-only control, Ad-∆B7/IL12/GMCSF only (5 × 109 VP/injection), DCs 
only (1 × 106 cells/injection), or a combination of DCs and Ad-∆B7/IL12/
GMCSF). In parallel, one group of mice was given a treatment regimen of a 
high dose of Ad-∆B7/IL12/GMCSF (5 × 1010 VP/injection) in combination 
with DCs (1 × 106/injection). Tumor-bearing mice were intratumorally 
injected with three doses of Ad on days 0–2, followed by three injections 
of DCs on days 3–5. Tumor growth was monitored every other day using 
a caliper, and tumor volume was calculated by the following formula: vol-
ume = 0.523 LW2, where L is length and W is width. Animals with tumors 
that were >3,000 mm3 were killed for ethical reasons.
Expression of IL-12 and GM-CSF. IL-12 and GM-CSF expression were 
determined using an ELISA according to the manufacturer’s instructions. 
B16-F10 melanoma cells were plated onto six-well plates at 1 × 104 per 
well and then infected with Ad-∆B7/IL12/GMCSF at MOIs of 50, 100, and 
500. At 48 hour after infection, supernatants were harvested and the level 
of IL-12 and GM-CSF was determined with conventional IL-12 ELISA kit 
(ENDOGEN) and GM-CSF ELISA kit (R&D systems, Minneapolis, MN), 
respectively. For the assessment of cytokine expression in tumor tissue, 
tumor tissues were removed from mice treated with Ad and/or DCs at 3 
days after final treatment. Tissues were homogenized and liquefied in PBS 
containing protease inhibitor cocktail (Sigma). IL-12, GM-CSF, VEGF, and 
TNF-α level were measured by conventional ELISA kits (ENDOGEN and 
R&D systems). Each experiment was carried out three to four times with 
three replicates in each group.
Histology and immunohistochemistry. Tumor tissues were harvested 
from mice after 3 days of final treatment, and embedded in paraffin and 
sectioned at a thickness of 4 μm for hematoxylin and eosin (H&E) stain-
ing. For immunohistochemical staining, tumor tissues were snap-frozen 
and sectioned at a thickness of 7 μm. Tumor sections were blocked with 
4% PBS–bovine serum albumin (Sigma) for 1 hour and incubated over 
night with appropriate dilution of anti-CD4 (purified rat anti-mouse 
CD4 monoclonal Ab; Pharmingen), anti-CD8 (purified rat anti-mouse 
CD8 monoclonal Ab; Pharmingen), anti-CD86 (purified rat anti-mouse 
CD86  monoclonal  Ab;  Pharmingen),  anti-CD11c  (purified  hamster 
anti-mouse  CD11c  monoclonal  Ab;  Pharmingen),  or  anti-CCL21 
(purified rat anti-mouse CCL21 monoclonal Ab; R&D systems) in Ab 
diluents (DAKO, Glostrup, Denmark). After overnight incubation, the 
sections were washed twice in PBS and incubated with horseradish per-
oxidase-conjugated goat anti-rat or mouse anti-hamster Ab (Southern 
Biotechnology,  Birmingham,  AL)  for  1  hour  Diaminobenzidine/Molecular Therapy  vol. 19 no. 8 aug. 2011  1567
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hydrogen peroxidase (DAKO) was used as the chromogen substrate. All 
slides were counterstained with Meyer’s hematoxylin.
Evaluation of DC migration in vivo. DCs were labeled with CellTracker 
Red CMTPX (Invitrogen, Carlsbad, CA) on day 6 of DC culture and 
were harvested on day 8. The tumor-bearing mice were intratumorally 
injected with DCs (1 × 106/time) alone three times every day or intra-
tumorally injected with Ad-∆B7/IL12/GMCSF (5 × 109 VP/time or 5 × 
1010 VP/time) three times every day prior to DC injection. At 48 hour 
after final treatment, the DLNs were harvested and dissociated into single 
cells for FACS analysis. The number of CMTPX+ DCs and CD11c+ DCs 
was quantified on a fluorescence-activated cell sorter (Becton Dickinson, 
Sunnyvale, CA) and data from 50,000 events were collected for further 
analysis.
Statistical analysis. The data was expressed as mean ± SE. Statistical 
analyses of the data were performed using the two-tailed Student’s t-test 
(SPSS 13.0 software; SPSS, Chicago, IL). P values of <0.05 were considered 
statistically significant (*P < 0.05; **P < 0.01). Analysis of variance was 
used for multiple group comparison on antitumor effect examination.
suPPleMentArY MAterIAl
Figure S1.  Characterization of bone marrow-derived DCs.
Figure S2.  DC migration assay in vivo.
Figure S3.  Fluorescence-activated cell sorting analysis of CD4+CD25+ 
T-cells in draining lymph nodes (DLNs) from mice treated with   Ad-∆B7/
IL12/GMCSF and/or DCs.
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